| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 10.16▲ | 10.16▲ | 10.16▲ | 10.18▲ | 10.16▲ |
| MA10 | 10.15▲ | 10.15▲ | 10.14▲ | 10.17▲ | N/A |
| MA20 | N/A | N/A | N/A | 10.16▲ | N/A |
| MA50 | N/A | N/A | N/A | N/A | N/A |
| MA100 | N/A | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | N/A | N/A |
| RSI | 73.849▲ | N/A | N/A | 60.253▲ | N/A |
| STOCH | N/A | N/A | N/A | 70.808 | N/A |
| WILL %R | 0.000▲ | 0.000▲ | N/A | -28.571 | N/A |
| CCI | 162.791▲ | 162.791▲ | N/A | 104.296▲ | N/A |
|
Wednesday, August 19, 2026 10:25 AM
What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 6.9% in the afternoon session after positive trial results from peers Moderna and Merck for their personalized ...
|
|
Tuesday, August 11, 2026 04:47 AM
Vaccine biotechnology company Novavax (NASDAQ:NVAX) announced better-than-expected revenue in Q2 CY2026, but sales fell by 76.3% year on year to $56.7 million. Its GAAP loss of $0.32 per share was 16.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 21/08/26 | 10.18 | 10.1874 | 10.18 | 10.18 | 10,481 |
| 20/08/26 | 10.17 | 10.20 | 10.165 | 10.19 | 13,262 |
| 19/08/26 | 10.17 | 10.17 | 10.17 | 10.17 | 194 |
| 18/08/26 | 10.17 | 10.17 | 10.1501 | 10.17 | 36,280 |
| 17/08/26 | 10.17 | 10.17 | 10.15 | 10.17 | 122,362 |
| 14/08/26 | 10.17 | 10.185 | 10.17 | 10.17 | 37,958 |
| 13/08/26 | 10.17 | 10.17 | 10.165 | 10.17 | 13,710 |
| 12/08/26 | 10.1612 | 10.1662 | 10.16 | 10.165 | 7,216 |
| 11/08/26 | 10.18 | 10.18 | 10.1799 | 10.1799 | 1,258 |
| 10/08/26 | 10.17 | 10.18 | 10.165 | 10.18 | 11,994 |
|
|
||||
|
|
||||
|
|